Kaken Pharmaceutical Co. Ltd
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regrot… Read more
Kaken Pharmaceutical Co. Ltd (KKPCF) - Net Assets
Latest net assets as of December 2025: $145.94 Billion USD
Based on the latest financial reports, Kaken Pharmaceutical Co. Ltd (KKPCF) has net assets worth $145.94 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($176.59 Billion) and total liabilities ($30.66 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $145.94 Billion |
| % of Total Assets | 82.64% |
| Annual Growth Rate | 6.24% |
| 5-Year Change | 12.02% |
| 10-Year Change | 69.83% |
| Growth Volatility | 6.19 |
Kaken Pharmaceutical Co. Ltd - Net Assets Trend (2005–2025)
This chart illustrates how Kaken Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kaken Pharmaceutical Co. Ltd (2005–2025)
The table below shows the annual net assets of Kaken Pharmaceutical Co. Ltd from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $152.63 Billion | +6.18% |
| 2024-03-31 | $143.75 Billion | +5.06% |
| 2023-03-31 | $136.84 Billion | -1.08% |
| 2022-03-31 | $138.32 Billion | +1.52% |
| 2021-03-31 | $136.26 Billion | +6.06% |
| 2020-03-31 | $128.47 Billion | +6.06% |
| 2019-03-31 | $121.13 Billion | +6.37% |
| 2018-03-31 | $113.87 Billion | +10.93% |
| 2017-03-31 | $102.65 Billion | +14.22% |
| 2016-03-31 | $89.87 Billion | +16.57% |
| 2015-03-31 | $77.10 Billion | +13.22% |
| 2014-03-31 | $68.09 Billion | +2.28% |
| 2013-03-31 | $66.58 Billion | +7.26% |
| 2012-03-31 | $62.07 Billion | +2.81% |
| 2011-03-31 | $60.38 Billion | +1.34% |
| 2010-03-31 | $59.58 Billion | +5.11% |
| 2009-03-31 | $56.68 Billion | -1.34% |
| 2008-03-31 | $57.45 Billion | -4.93% |
| 2007-03-31 | $60.43 Billion | +10.60% |
| 2006-03-31 | $54.64 Billion | +20.11% |
| 2005-03-31 | $45.49 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kaken Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 951.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $135.24 Billion | 88.61% |
| Common Stock | $23.85 Billion | 15.63% |
| Total Equity | $152.63 Billion | 100.00% |
Kaken Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of Kaken Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eyepoint Pharmaceuticals Inc
NASDAQ:EYPT
|
$859.93 Million |
|
Hubei Jianghan New Materials Co. Ltd. A
SHG:603281
|
$860.13 Million |
|
BALTIC CLASSIF.GR LS 001
F:983
|
$860.39 Million |
|
Can Fin Homes Limited
NSE:CANFINHOME
|
$860.40 Million |
|
Puuilo Oyj
HE:PUUILO
|
$859.36 Million |
|
Zhejiang Shaoxing RuiFeng Rural Commercial Bank Co Ltd
SHG:601528
|
$858.70 Million |
|
Scandinavian Tobacco Group A/S
PINK:SNDVF
|
$858.64 Million |
|
Res Robex Inc
V:RBX
|
$858.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kaken Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 143,755,000,000 to 152,634,000,000, a change of 8,879,000,000 (6.2%).
- Net income of 13,945,000,000 contributed positively to equity growth.
- Dividend payments of 7,198,000,000 reduced retained earnings.
- Share repurchases of 5,935,000,000 reduced equity.
- New share issuances of 7,764,000,000 increased equity.
- Other comprehensive income decreased equity by 8,547,000,000.
- Other factors increased equity by 8,850,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $13.95 Billion | +9.14% |
| Dividends Paid | $7.20 Billion | -4.72% |
| Share Repurchases | $5.93 Billion | -3.89% |
| Share Issuances | $7.76 Billion | +5.09% |
| Other Comprehensive Income | $-8.55 Billion | -5.6% |
| Other Changes | $8.85 Billion | +5.8% |
| Total Change | $- | 6.18% |
Book Value vs Market Value Analysis
This analysis compares Kaken Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | $758.57 | $26.31 | x |
| 2006-03-31 | $934.71 | $26.31 | x |
| 2007-03-31 | $1072.28 | $26.31 | x |
| 2008-03-31 | $1082.56 | $26.31 | x |
| 2009-03-31 | $1129.74 | $26.31 | x |
| 2010-03-31 | $1217.11 | $26.31 | x |
| 2011-03-31 | $1291.82 | $26.31 | x |
| 2012-03-31 | $1385.87 | $26.31 | x |
| 2013-03-31 | $1529.77 | $26.31 | x |
| 2014-03-31 | $1596.67 | $26.31 | x |
| 2015-03-31 | $1850.07 | $26.31 | x |
| 2016-03-31 | $2170.19 | $26.31 | x |
| 2017-03-31 | $2502.41 | $26.31 | x |
| 2018-03-31 | $2813.76 | $26.31 | x |
| 2019-03-31 | $3037.82 | $26.31 | x |
| 2020-03-31 | $3282.24 | $26.31 | x |
| 2021-03-31 | $3530.86 | $26.31 | x |
| 2022-03-31 | $3626.97 | $26.31 | x |
| 2023-03-31 | $3626.65 | $26.31 | x |
| 2024-03-31 | $3809.39 | $26.31 | x |
| 2025-03-31 | $3999.63 | $26.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kaken Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.14%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.83%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 1.25x
- Recent ROE (9.14%) is below the historical average (11.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 7.51% | 4.56% | 0.69x | 2.39x | $-1.13 Billion |
| 2006 | 7.11% | 5.15% | 0.76x | 1.81x | $-1.58 Billion |
| 2007 | 7.62% | 6.02% | 0.76x | 1.67x | $-1.44 Billion |
| 2008 | 8.89% | 6.39% | 0.85x | 1.63x | $-638.70 Million |
| 2009 | 9.84% | 6.73% | 0.88x | 1.67x | $-88.90 Million |
| 2010 | 11.30% | 7.92% | 0.89x | 1.60x | $776.50 Million |
| 2011 | 13.60% | 9.50% | 0.88x | 1.63x | $2.18 Billion |
| 2012 | 13.34% | 9.41% | 0.84x | 1.69x | $2.07 Billion |
| 2013 | 13.50% | 10.33% | 0.80x | 1.64x | $2.33 Billion |
| 2014 | 14.30% | 10.94% | 0.84x | 1.56x | $2.93 Billion |
| 2015 | 15.72% | 12.91% | 0.82x | 1.49x | $4.41 Billion |
| 2016 | 23.53% | 19.36% | 0.82x | 1.48x | $12.16 Billion |
| 2017 | 21.45% | 21.59% | 0.76x | 1.32x | $11.75 Billion |
| 2018 | 16.72% | 19.35% | 0.65x | 1.34x | $7.66 Billion |
| 2019 | 14.67% | 18.88% | 0.60x | 1.29x | $5.66 Billion |
| 2020 | 15.08% | 21.71% | 0.57x | 1.23x | $6.52 Billion |
| 2021 | 9.84% | 17.88% | 0.46x | 1.20x | $-220.60 Million |
| 2022 | 6.93% | 12.56% | 0.46x | 1.20x | $-4.23 Billion |
| 2023 | 3.99% | 7.45% | 0.44x | 1.22x | $-8.19 Billion |
| 2024 | 5.58% | 11.14% | 0.42x | 1.19x | $-6.35 Billion |
| 2025 | 9.14% | 14.83% | 0.49x | 1.25x | $-1.32 Billion |
Industry Comparison
This section compares Kaken Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kaken Pharmaceutical Co. Ltd (KKPCF) | $145.94 Billion | 7.51% | 0.21x | $859.70 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |